echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Oncternal Therapeutics has worked with the Karolinska Institute to develop CAR-T and CAR-NK cell therapies targeted at RUR1

    Oncternal Therapeutics has worked with the Karolinska Institute to develop CAR-T and CAR-NK cell therapies targeted at RUR1

    • Last Update: 2021-01-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Biopharmaceutical company Oncternal Therapeutics today announced that it has established a research and development partnership with the Karolinska Institute in Sweden to advance CAR-T cell and CAR-NK cell therapies targeted at RUR1.
    Dr Hans-Gustaf Ljunggren, of the NextGenNK Centre at the Karolinska Institute, said: "Given that NK cells were discovered at the Karolinska Institute, we are pleased to work with industry partners to translate scientific advances into next-generation cell therapies that benefit cancer patients.
    We look forward to working with Oncternal to develop T-cell and NK cell therapies for ROR1, an effective target for many oncology adaptations," said Dr. James Breitmeyer, President and CEO of Oncternal.
    ROR1 has become an important and undeveloped target for cancer treatment, and we believe that CAR-T and CAR-NK treatments targeting RUR1 have significant prospects for both hematopathic and solid tumor patients."
    OR1 is considered a very promising target because it is located on the surface of the cell and, more importantly, it is highly expressed in tumor cells and very low in adult healthy tissue.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.